<DOC>
	<DOCNO>NCT00417898</DOCNO>
	<brief_summary>This study determine safety 500mg aspirin add IV TPA standard dose prevent re-occlusion cerebral vessel successful reperfusion . In ischemic stroke brain artery occlude either embolus originate heart large vessel lead brain process acute thrombosis cerebral artery rupture atherosclerotic plaque . Rupture plaque expose thrombogenic element within plaque lead accumulation activation platelet induction clot cascade eventually lead acute thrombosis occlusion artery . TPA currently approve Food Drug Administration treat heart brain problem cause blockage artery . It activate plasminogen lead disintegration thrombus/embolus . It effective begin within 3 4.5 hour onset stroke potential deleterious side effect include life threaten symptomatic intracranial hemorrhage ( sICH ) drug administer outside time window . Reperfusion ischemic brain ( i.e . timely open occlude artery ) TPA associate improved outcome . However , 33 % patient successfully reperfused TPA artery re-occludes within first hour result worsen neurological symptom worse functional outcome . This re-occlusion speculate result re-thrombosis exist rupture atherosclerotic plaque . This explain relatively short half life TPA leave expose ruptured plaque intact lead re-activation platelet clot factor re-thrombosis . Thus , hypothesize addition antiplatelet agent TPA would result low rate re-occlusion AIS . The FDA approve TPA patient AIS discourage concomitant use anti-platelet anti-thrombotic drug first 24hours administration TPA concern therapy may result increase rate intracerebral hemorrhage . Aspirin well known platelet anti-aggregant work inhibition cycloxygenase 1 reduction thromboxane A level . It rapid onset action additional potential beneficial anti-inflammatory effect patient AIS . The international stroke study show acute treatment stroke patient 500mg aspirin safe feasible result well outcome . Furthermore , drug safe circumstance ICH rate . Therefore , purpose clinical trial examine safety efficacy combination aspirin rt-TPA patient AIS .</brief_summary>
	<brief_title>Study Aspirin TPA Acute Ischemic Stroke</brief_title>
	<detailed_description>Background Objectives : Management acute ischemic stroke consist thrombolytic drug aim opening occlude vessel . Tissue plasminogen activator ( TPA ) drug approve FDA ( 1 , 2 ) . The use TPA significantly limit relatively narrow therapeutic window 3-4.5 hour follow stroke onset ( 3 , 4 ) . Use TPA outside time window associate unacceptably high risk hemorrhage include symptomatic intracranial hemorrhage ( sICH ) ( 5 , 6 ) . While TPA efficacious reduce stroke associate disability effect limit phenomenon early re-occlusion successful reperfusion occlude artery . Previous report show among patient receive IV TPA within 3 hour stroke onset 61 % re-perfuse 1 hour , 67 % partial recanalization 33 % complete recanalization occlude artery ( 7 ) . reperfusion rate 2 hour tend much low range around 30-40 % imply early re-occlusion ( 8 ) . Indeed find 25 % patient successfully reperfused re-occlude artery within 2 hour ( 7 ) . Re-occlusion already reperfused artery common elderly patient severe ipsilateral carotid stenosis high NIHSS score associate poor outcome ( 7 ) . We speculate re-occlusion much common atherothrombotic stroke compare embolic stroke . In embolic stroke TPA disintegrate occlude embolus frequently remain expose endothelium plaque would trigger thrombosis ( 9 ) . In contrast , atherothrombotic stroke TPA disintegrate occlude thrombus lead re-perfusion less frequently ( 9 ) expose thrombogenic element within rupture plaque remain place trigger repeat platelet activation re-thrombosis . Because primary reperfusion less frequent patient atherothrombotic large vessel stroke re-occlusion common patient process involve platelet aggregation activation site thrombosis argue addition anti-platelet agent would able increase reperfusion rate decrease re-occlusion rate patient . Aspirin commonly use antiplatelet agent stroke patient . It relatively long half life relatively rapid onset therapeutic effect ( 10 , 11 ) . Furthermore , additional aspirin bolus may reverse state aspirin resistance patient suffer stroke aspirin ( 12 , 13 ) . Aspirin safe give patient acute stroke soon diagnosis make ( 14 , 15 ) . Because FDA approval TPA use stroke patient pre-requisite use concurrent anti-thrombotic drug 24 hour TPA administration safety aspirin need study randomized trial . However , note pre-TPA aspirin use associate increase ICH risk patient give drug ( 16 ) therefore pre-morbid aspirin use consider contraindication TPA administration acute stroke . The study randomize double blind study explore safety add 500 mg aspirin give P.O . standard dose IV TPA . STUDY ENDPOINTS : PRIMARY ENDPOINT 1 . Safety ( mortality , symptomatic ICH , asymptomatic ICH ) . SECONDARY ENDPOINTS 1 . Proportion patient achieve excellent functional outcome determine modified Rankin score ( mRS ) &lt; 2 Barthel index ( BI ) &gt; 85 obtain 3 month stroke onset . 2 . Good neurological outcome assess NIH stroke scale score discharge &lt; 5 show improvement least 8 point initial stroke score . 3 . Good neurological outcome assess NIH stroke scale score 3 month &lt; 5 show improvement least 8 point initial stroke score . Inclusion Exclusion Criteria INCLUSION CRITERIA : Patients must meet inclusion criterion . 1 . Diagnosis acute ischemic stroke onset less 4.5 hour prior plan start intravenous alteplase . Acute ischemic stroke define measurable neurological deficit sudden onset , presume secondary focal cerebral ischemia . Stroke onset defined time patient last know without new clinical deficit . Patients whose deficit worsen last 4.5 hour eligible first symptom start 4.5 hour . If stroke start sleep , stroke onset recorded time patient last known baseline . 2 . Disabling neurological deficit attributable acute ischemic stroke middle cerebral artery territory . 3 . NIHSS le equal 18 leave hemisphere stroke , NIHSS le equal 16 others . 4 . Evidence MCA occlusion ( stem branch ) prior drug administration TCD , CTA MRA . 5 . Age 18-85 year , inclusive . 6 . Able sign inform consent . EXCLUSION CRITERIA : Patients exclude study participation follow reason : 1 . Current participation another study investigational drug device within , prior participation present study , plan participation another therapeutic trial , prior final ( day 30 ) assessment trial . 2 . Absence acoustic window insonate MCA involve side . 3 . Time interval since stroke onset le 3 hour impossible determine high degree confidence . 4 . Symptoms suggestive subarachnoid hemorrhage , even CT MRI scan negative hemorrhage . 5 . Evidence acute myocardial infarction define least two follow three feature : 1 ) Chest pain suggestive cardiac ischemia ; 2 ) EKG finding ST elevation great 0.2 mV 2 contiguous lead , new onset leave bundle branch block , ST segment depression , T-wave inversion ; 3 ) Elevated troponin I . 6 . Acute Pericarditis . 7 . Women know pregnant , lactate positive indeterminate pregnancy test . 8 . Neurological deficit lead stupor coma ( NIHSS level consciousness [ item I ] score great equal 2 ) . 9 . High clinical suspicion septic embolus . 10 . Minor stroke non-disabling deficit rapidly improve neurological symptom . 11 . Baseline NIHSS great 18 leave hemisphere stroke great 16 others . 12 . Evidence acute chronic ICH head CT MRI . 13 . CT MRI evidence non-vascular cause neurological symptom . 14 . Signs mass effect cause shift midline structure CT MRI . 15 . Persistent hypertension systolic BP great 185 mmHg diastolic BP great 110 mmHg ( mean 3 consecutive arm cuff reading 20-30 minute ) , control antihypertensive therapy require nitroprusside control . 16 . Anticipated need major surgery within 72 hour start study drug , e.g. , carotid endarterectomy , hip fracture repair . 17 . Any intracranial surgery , intraspinal surgery , serious head trauma ( head injury require hospitalization ) within past 3 month . 18 . Stroke within past 3 month . 19 . History ICH time past . 20 . Major trauma time stroke , e.g. , hip fracture . 21 . Blood glucose great 200 mg/dl . 22 . Presence history intracranial neoplasm ( except small meninigiomas ) arteriovenous malformation . 23 . Intracranial aneurysm , unless surgically endovascularly treat 3 month . 24 . Seizure onset stroke . 25 . Active internal bleeding . 26 . Major hemorrhage ( require transfusion , surgery hospitalization ) past 21 day . 27 . Major surgery , serious trauma , lumbar puncture , arterial puncture non-compressible site , biopsy parenchymal organ last 14 day . Major surgical procedure include limited following : major thoracic abdominopelvic surgery , neurosurgery , major limb surgery , carotid endarterectomy vascular surgery , organ transplantation . For non-listed procedure , operate surgeon consult assess risk . 28 . Presumed documented history vasculitis . 29 . Known systemic bleeding platelet disorder , e.g. , von Willebrand 's disease , hemophilia , ITP , TTP , others . 30 . Platelet count less 100,000 cells/micro L. 31 . Congenital acquire coagulopathy ( e.g. , secondary anticoagulant ) cause either follow : 1 . Activated partial thromboplastin time ( aPTT ) prolongation great 2 second upper limit normal local laboratory , except due isolated factor XII deficiency . 2 . INR great equal 1.4 . Patients receive warfarin prior entry eligible provide INR le 1.4 warfarin safely discontinue least 48 hour . 32 . Life expectancy le 3 month . 33 . Other serious illness , e.g. , severe hepatic , cardiac , renal failure ; acute myocardial infarction ; complex disease may confound treatment assessment . 34 . Severe renal failure : Serum creatinine great 4.0 mg/dL dependency renal dialysis . 35 . AST ALT great 3 time upper limit normal local laboratory . 36 . Treatment qualify stroke thrombolytic , anti-thrombotic GPIIbIIIa inhibitor outside protocol . 37 . Any administration thrombolytic drug prior 7 day . 38 . Treatment qualify stroke intravenous heparin unless aPTT prolongation great 2 second upper limit normal local laboratory prior study drug initiation . 39 . Treatment qualify stroke low molecular weight heparin heparinoid . 40 . Known hypersensitivity TPA . 41 . Anticoagulation ( evidence abnormal INR , aPTT , platelet count ) cause herbal therapy . METHOD : Eligible patient ( n=20/group ) recruit obtain informed consent . Patients randomized receive rt-TPA 0.9mg/kg ( 10 % total dose IV bolus reminder IV 60 minute ) + placebo rt-TPA 0.9mg/kg + aspirin P.O . dose 500mg time TPA administration.. Randomization accomplish use IVRS automate system . Randomization time tier 0-1.5 hour symptom onset , 1.5-3 hour symptom onset 3-4.5 hour symptom onset dose tier . Overall 60 patient ( 30 TPA + active drug 30 TPA recruit ) . Study medication supply hospital total volume , color odor identical placebo . At end recruitment randomization code open data safety monitor board ( DSMB ) determine safety continue study next dose tier . Samples collect safety data ( renal , hepatic coagulation study ) send local laboratory center . Investigators notify immediately lab result fax email . ECGs read central facility investigator notify abnormal result immediately via fax email . All AE SAE report immediately . EVALUATIONS Safety : Hemodynamics : Patients monitor non-invasively blood pressure , heart rate , oxygen saturation q2rhs first 24 hour post stroke every 6 hour next 24 hour every 12 hour reminder hospitalization . Coagulation test : PT , PTT PLT blood count evaluate daily first 3 day hospitalization . Blood test : Blood chemistry , liver function test cardiac enzymes evaluate daily first 3 day discharge . Cardiac rhythm : ECG evaluate daily 12 lead record first 3 day hospitalization discharge . CT : Brain CT obtain prior drug administration include patient repeat scan obtain 96-120 hour evaluate final infarct size . In case suspect hematoma brain CT would obtain immediately number patient sustain ICH follow drug administration record . All adverse event ( AE ) serious adverse event ( SAE ) record promptly evaluate data safety monitor board decide whether event drug relate authority prematurely terminate study case unexpected SAE emerge appear drug relate . AE SAE define conventionally AE adverse event SAE AE necessitate prolongation hospitalization adverse event potentially life threaten ) . NEUROLOGICAL Included patient examine randomization National Institute Health stroke scale ( NIHSS ) day 1,2,3,5 discharge outpatient visit month 1 3-post stroke . FUNCTIONAL OUTCOME Patients evaluate Barthel index ( BI ) modify Rankin score ( MRS ) administer discharge day outpatient visit month 1 3-post stroke . References : 1 . Tissue plasminogen activator acute ischemic stroke . The National Institute Neurological Disorders Stroke rt-PA Stroke Study Group . N Engl J Med . 1995 ; 333:1581-1587 2 . Hacke W , Kaste M , Fieschi C et al . Intravenous thrombolysis recombinant tissue plasminogen activator acute hemispheric stroke . The European Cooperative Acute Stroke Study ( ECASS ) . JAMA . 1995 ; 274:1017-1025 3 . Albers GW , Bates VE , Clark WM et al . Intravenous tissue-type plasminogen activator treatment acute stroke : Standard Treatment Alteplase Reverse Stroke ( STARS ) study . JAMA . 2000 ; 283:1145-1150 4 . Hacke W , Donnan G , Fieschi C et al . Association outcome early stroke treatment : pool analysis ATLANTIS , ECASS , NINDS rt-PA stroke trial . Lancet . 2004 ; 363:768-774 5 . Graham GD . Tissue plasminogen activator acute ischemic stroke clinical practice : meta-analysis safety data . Stroke . 2003 ; 34:2847-2850 6 . Burgin WS , Staub L , Chan W et al . Acute stroke care non-urban emergency department . Neurology . 2001 ; 57:2006-2012 7 . Rubiera M , Alvarez-Sabin J , Ribo M et al . Predictors early arterial reocclusion tissue plasminogen activator-induced recanalization acute ischemic stroke . Stroke . 2005 ; 36:1452-1456 8 . Molina CA , Ribo M , Rubiera M et al . Microbubble administration accelerate clot lysis continuous 2-MHz ultrasound monitoring stroke patient treat intravenous tissue plasminogen activator . Stroke . 2006 ; 37:425-429 9 . Molina CA , Montaner J , Arenillas JF et al . Differential pattern tissue plasminogen activator-induced proximal middle cerebral artery recanalization among stroke subtypes . Stroke . 2004 ; 35:486-490 10 . Barnett HJ . Aspirin stroke prevention . An overview . Stroke . 1990 ; 21 : IV40-43 11 . Schror K. Antiplatelet drug . A comparative review . Drugs . 1995 ; 50:7-28 12 . Wang TH , Bhatt DL , Topol EJ . Aspirin clopidogrel resistance : emerge clinical entity . Eur Heart J . 2006 ; 27:647-654 13 . Sztriha LK , Sas K , Vecsei L. Aspirin resistance stroke : 2004 . J Neurol Sci . 2005 ; 229-230:163-169 14 . The International Stroke Trial ( IST ) : randomise trial aspirin , subcutaneous heparin , , neither among 19435 patient acute ischaemic stroke . International Stroke Trial Collaborative Group . Lancet . 1997 ; 349:1569-1581 15 . CAST : randomise placebo-controlled trial early aspirin use 20,000 patient acute ischaemic stroke . CAST ( Chinese Acute Stroke Trial ) Collaborative Group . Lancet . 1997 ; 349:1641-1649 16 . Levy DE , Brott TG , Haley EC , Jr. et al . Factors related intracranial hematoma formation patient receive tissue-type plasminogen activator acute ischemic stroke . Stroke . 1994 ; 25:291-297</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Patients must meet inclusion criterion . 1 . Diagnosis acute ischemic stroke onset less 4.5 hour prior plan start intravenous alteplase . Acute ischemic stroke define measurable neurological deficit sudden onset , presume secondary focal cerebral ischemia . Stroke onset defined time patient last know without new clinical deficit . Patients whose deficit worsen last 4.5 hour eligible first symptom start 4.5 hour . If stroke start sleep , stroke onset recorded time patient last known baseline . 2 . Disabling neurological deficit attributable acute ischemic stroke middle cerebral artery territory . 3 . NIHSS le equal 18 leave hemisphere stroke , NIHSS le equal 16 others . 4 . Evidence MCA occlusion ( stem branch ) prior drug administration TCD , CTA MRA . 5 . Age 1885 year , inclusive . 6 . Able sign inform consent . For MRI Arm : 7 . Screening MRI diagnostic focal cerebral ischemia correspond clinical deficit . The MRI evaluation must involve echo planar diffusion weight imaging , MRA , MRI perfusion . A normal appear MRA appropriate perfusion deficit eligible . An apparent stenosis occlusion MRA normal appear perfusion distally eligible . Poor quality uninterpretable MRA make patient ineligible . Patients normal appear DWI eligible . 8 . Evidence PWI MRI perfusion defect correspond acute stroke syndrome . The PWI assess relative mean transit time ( MTT ) image obtain prior start rtTPA therapy . Patients exclude study participation follow reason : 1 . Current participation another study investigational drug device within , prior participation present study , plan participation another therapeutic trial , prior final ( day 30 ) assessment trial . 2 . Absence acoustic window insonate MCA involve side . 3 . Time interval since stroke onset le 3 hour impossible determine high degree confidence . 4 . Symptoms suggestive subarachnoid hemorrhage , even CT MRI scan negative hemorrhage . 5 . Evidence acute myocardial infarction define least two follow three feature : 1 ) Chest pain suggestive cardiac ischemia ; 2 ) EKG finding ST elevation great 0.2 mV 2 contiguous lead , new onset leave bundle branch block , ST segment depression , Twave inversion ; 3 ) Elevated troponin I . 6 . Acute Pericarditis . 7 . Women know pregnant , lactate positive indeterminate pregnancy test . 8 . Neurological deficit lead stupor coma ( NIHSS level consciousness [ item I ] score great equal 2 ) . 9 . High clinical suspicion septic embolus . 10 . Minor stroke nondisabling deficit rapidly improve neurological symptom . 11 . Baseline NIHSS great 18 leave hemisphere stroke great 16 others . 12 . Evidence acute chronic ICH head CT MRI . 13 . CT MRI evidence nonvascular cause neurological symptom . 14 . Signs mass effect cause shift midline structure CT MRI . 15 . Persistent hypertension systolic BP great 185 mmHg diastolic BP great 110 mmHg ( mean 3 consecutive arm cuff reading 2030 minute ) , control antihypertensive therapy require nitroprusside control . 16 . Anticipated need major surgery within 72 hour start study drug , e.g. , carotid endarterectomy , hip fracture repair . 17 . Any intracranial surgery , intraspinal surgery , serious head trauma ( head injury require hospitalization ) within past 3 month . 18 . Stroke within past 3 month . 19 . History ICH time past . 20 . Major trauma time stroke , e.g. , hip fracture . 21 . Blood glucose great 200 mg/dl . 22 . Presence history intracranial neoplasm ( except small meninigiomas ) arteriovenous malformation . 23 . Intracranial aneurysm , unless surgically endovascularly treat 3 month . 24 . Seizure onset stroke . 25 . Active internal bleeding . 26 . Major hemorrhage ( require transfusion , surgery hospitalization ) past 21 day . 27 . Major surgery , serious trauma , lumbar puncture , arterial puncture noncompressible site , biopsy parenchymal organ last 14 day . Major surgical procedure include limited following : major thoracic abdominopelvic surgery , neurosurgery , major limb surgery , carotid endarterectomy vascular surgery , organ transplantation . For nonlisted procedure , operate surgeon consult assess risk . 28 . Presumed documented history vasculitis . 29 . Known systemic bleeding platelet disorder , e.g. , von Willebrand 's disease , hemophilia , ITP , TTP , others . 30 . Platelet count less 100,000 cells/micro L. 31 . Congenital acquire coagulopathy ( e.g. , secondary anticoagulant ) cause either follow : 1 . Activated partial thromboplastin time ( aPTT ) prolongation great 2 second upper limit normal local laboratory , except due isolated factor XII deficiency . 2 . INR great equal 1.4 . Patients receive warfarin prior entry eligible provide INR le 1.4 warfarin safely discontinue least 48 hour . 32 . Life expectancy le 3 month . 33 . Other serious illness , e.g. , severe hepatic , cardiac , renal failure ; acute myocardial infarction ; complex disease may confound treatment assessment . 34 . Severe renal failure : Serum creatinine great 4.0 mg/dL dependency renal dialysis . 35 . AST ALT great 3 time upper limit normal local laboratory . 36 . Treatment qualify stroke thrombolytic , antithrombotic GPIIbIIIa inhibitor outside protocol . 37 . Any administration thrombolytic drug prior 7 day . 38 . Treatment qualify stroke intravenous heparin unless aPTT prolongation great 2 second upper limit normal local laboratory prior study drug initiation . 39 . Treatment qualify stroke low molecular weight heparin heparinoid . 40 . Known hypersensitivity TPA . 41 . Anticoagulation ( evidence abnormal INR , aPTT , platelet count ) cause herbal therapy . FOR nonMRI arm ( # 4243 ) : 42 . Ischemic change screen CT great approximately one third territory middle cerebral artery territory qualitative assessment . 43 . Patients exclude screen MRI , except exclusion # 45 ( contraindication MRI ) # 46 ( PWI obtain uninterpretable ) # 50 ( MRI obtainable would put patient 3 hour time window alteplase ) . FOR MRI arm ( # 4451 ) : 44 . Contraindication MRI scan . 45 . PWI obtain uninterpretable . 46 . No MTT defect correspond acute stroke deficit . 47 . DWI abnormality large approximately one third territory middle cerebral artery territory qualitative assessment . 48 . Satellite DWI hyperintensity correspond hyperintensity T2 weight image FLAIR vascular territory different index stroke ( evidence new ischemic lesion great 3 hour duration ) . 49 . Evidence multiple microbleeds gradient echo MRI ( GRE ) . 50 . MRI obtain would put patient 3 hour time window alteplase .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Stroke</keyword>
	<keyword>Cerebral Ischemia</keyword>
	<keyword>Tissue Plasminogen Activator</keyword>
	<keyword>Aspirin</keyword>
	<keyword>Human</keyword>
	<keyword>Cerebral Reperfusion</keyword>
</DOC>